For the treatment of BRD, the effect of Zactran was studied in comparison to another macrolide antibiotic (tulathromycin) already authorised in the EU, in cattle already affected by the disease.
Veiste hingamisteede haiguse ravis kasutamiseks võrreldi Zactrani teise makroliidide rühma kuuluva haigust põdevate veiste ravis kasutatava antibiootikumiga (tulatromütsiin), millele on Euroopa Liidus müügiluba juba antud.